|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
1/30/2013 9:33:42 AM
NEW YORK, Jan. 29, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, today announced the exercise in full of the over-allotment option granted to the representative of the underwriters by Stemline with respect to the purchase of 497,647 shares of common stock at a public offering price of $10.00 per share, less underwriting discounts and commissions. The over-allotment option is being exercised in connection with Stemline's previously announced initial public offering of 3,317,644 shares of common stock. As a result of the exercise of the over-allotment option, the total gross proceeds to Stemline from the offering will be $38,152,910, before deducting underwriting discounts and commissions and other offering expenses.
|
|
|
|
|
|
|
|
|
|
|